Evidence map›Paper›PMID 34247184›Full record

ArticleTranslational psychiatry2021

Importance of test-retest reliability for promoting fMRI based screening and interventions in major depressive disorder.

Laurie Compère, Greg J Siegle, Kymberly Young

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Neuroimaging for precision medicine in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Laurie CompèreDepartment of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA. ljc44@pitt.edu.ORCID http://orcid.org/0000-0001-7002-732X
Greg J SiegleDepartment of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA.
Kymberly YoungDepartment of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA.
University of Pittsburgh · US

Funding

PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058356 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THASE, MICHAEL E · 2000 to 2010
$3.5M
Functional Neuroanatomy of Recovery from DepressionR01MH074807 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIEGLE, GREG J · 2006 to 2010
$1.9M
Amygdala rtfMRI Neurofeedback for Treatment Resistant DepressionR33MH115927 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YOUNG, KYM · 2022 to 2024
$1.7M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069618 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, EDWARD S. · 2004 to 2008
$1.5M
Amygdala rtfMRI Neurofeedback for Treatment Resistant DepressionR61MH115927 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YOUNG, KYM · 2018 to 2019
$1.2M
Graduated sensory salience as an intervention for intrusive negative thinkingR33MH106591 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIEGLE, GREG J · 2018 to 2020
$989k
Graduated sensory salience as an intervention for intrusive negative thinkingR21MH106591 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIEGLE, GREG J · 2015 to 2016
$618k
NIMH NIH HHS R01 MH058356NIMH NIH HHS R01 MH069618NIMH NIH HHS R01 MH074807NIMH NIH HHS R21 MH106591NIMH NIH HHS R33 MH106591NIMH NIH HHS R33 MH115927NIMH NIH HHS R61 MH115927
6 · The paper itself

Abstract

Proponents of personalized medicine have promoted neuroimaging in three areas of clinical application for major depression: clinical prediction, outcome evaluation, and treatment, via neurofeedback. Whereas psychometric considerations such as test-retest reliability are basic precursors to clinical adoption for most clinical instruments, we show, in this article, that basic psychometrics have not been regularly attended to in fMRI of depression. For instance, no fMRI neurofeedback study has included measures of test-retest reliability, despite the implicit assumption that brain signals are stable enough to train. We consider several factors that could be useful to aid clinical translation, including (1) attending to how the BOLD response is parameterized, (2) identifying and promoting regions or voxels with stronger psychometric properties, (3) accounting for within-individual changes (e.g., in symptomatology) across time, and (4) focusing on tasks and clinical populations that are relevant for the intended clinical application. We apply these principles to published prognostic and neurofeedback data sets. The broad implication of this work is that attention to psychometrics is important for clinical adoption of mechanistic assessment, is feasible, and may improve the underlying science.

Indexed as

Major Depressive DisorderNeurofeedbackBrainHumansMagnetic Resonance ImagingPsychometricsReproducibility of Results

Identifiers

PMID34247184
PMCPMC8272717
OpenAlexW3180944229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.